MediWound Ltd. (MDWD), a biopharmaceutical company, Tuesday said that data from the post hoc analysis of Phase 2 ChronEx study of EscharEx in patients with venous leg ulcers has been published in the peer-reviewed journal Wounds.
The analysis, based on the Phase II ChronEx study evaluating EscharEx compared with collagenase ointment, SANTYL showed that complete debridement was achieved in 63% of EscharEx-treated patients, at 2 weeks, compared to 0% in the SANTYL group.
Wound Bed Preparation or complete debridement and complete granulation was achieved by 50% of patients treated with EscharEx in 2 weeks vs. 0% with SANTYL, and Wound Closure was achieved in 33% of EscharEx patients vs. 25% with SANTYL.
"Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. EscharExs enzymatic formulation targets a wider range of non-viable and necrotic tissue, which may account for the favorable clinical outcomes observed," said Cyaandi Dove, DPM, of the University of Texas Health Science Center at San Antonio and co-author of the publication.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.